Mirum Pharmaceuticals (MIRM) Operating Expenses (2019 - 2026)

Mirum Pharmaceuticals' Operating Expenses history runs 8 years deep, the most recent figure standing at $949.3 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 648.89% year-over-year to $949.3 million; the TTM figure through Mar 2026 stood at $1.4 billion (up 199.85% YoY), while the FY2025 annual figure was $543.4 million, up 28.02% from the prior year.
• Operating Expenses was $949.3 million for Q1 2026 at Mirum Pharmaceuticals, up from $153.5 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $949.3 million in Q1 2026 to a low of $45.6 million in Q1 2022.
• Historically, Operating Expenses has averaged $142.4 million across 5 years, with a median of $102.1 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Operating Expenses decreased 4.17% in 2022, then soared 648.89% in 2026.
• A 5-year view of Operating Expenses shows it stood at $62.1 million in 2022, then jumped by 64.56% to $102.1 million in 2023, then climbed by 21.05% to $123.6 million in 2024, then gained by 24.15% to $153.5 million in 2025, then jumped by 518.47% to $949.3 million in 2026.
• The last three Operating Expenses figures came in at $949.3 million (Q1 2026), $153.5 million (Q4 2025), and $130.4 million (Q3 2025), per Business Quant data.